COLCRYS® (colchicine, USP) tablets

In response to the FDA’s initiative aimed at replacing older unapproved medicines with validated, agency approved medicines that meet modern standards for safety and efficacy, URL Pharma sponsored a clinical development program focused on colchicine, a compound used for centuries in the management of gout. The resulting trial, known as AGREE (Acute Gout Flare Receiving Colchicine Evaluation), revealed that a novel administration protocol for colchicine achieved efficacy outcomes comparable to historical dosing, but with markedly greater tolerability for patients. The AGREE data became the foundation for COLCRYS, which was approved for the prophylaxis and treatment of gout flares in 2009.

Learn more about how COLCRYS offers tough yet refined treatment for gout.